A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis

Patient-reported outcome measures in psoriasis: the good, the bad and the missing!

(2015) H. Kitchen et al.   BRITISH JOURNAL OF DERMATOLOGY

Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatology Life Quality Index (DLQI): Further Data

(2015) M.K.A. Basra et al.   DERMATOLOGY

ISA247: Quality of Life Results from a Phase II, Randomized, Placebo-Controlled Study

(2015) Aditya K. Gupta et al.   JOURNAL OF CUTANEOUS MEDICINE AND SURGERY

Effectiveness of Interdisciplinary vs. Dermatological Care of Moderate- to-severe Psoriasis: A Pragmatic Randomised Controlled Trial

(2014) J Schmitt et al.   ACTA DERMATO-VENEREOLOGICA

Quality of life in dermatology: after 125 years, time for more rigorous reporting

(2014) A.Y. Finlay   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study

(2014) D.S. Krupashankar et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients - a randomized placebo-controlled trial

(2014) A. Faurschou et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Patient-reported Functional Health and Well-Being Outcomes With Drug Therapy

(2014) Daniel M. Frendl et al.   MEDICAL CARE

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical efficacy of psoralen + sunlight vs. combination of isotretinoin and psoralen + sunlight for the treatment of chronic plaque-type psoriasis vulgaris: a randomized hospital-based study

(2014) Pratik Gahalaut et al.   PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE

A pilot study examining mindfulness-based cognitive therapy in psoriasis

(2014) B. Fordham et al.   Psychology Health & Medicine

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)

(2013) P J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical experience and psychometric properties of the Children's Dermatology Life Quality Index (CDLQI), 1995-2012

(2013) M.S. Salek et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2)

(2013) K. Reich et al.   BRITISH JOURNAL OF DERMATOLOGY

One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis

(2013) K. Reich et al.   BRITISH JOURNAL OF DERMATOLOGY

Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT)

(2013) C. Paul et al.   BRITISH JOURNAL OF DERMATOLOGY

Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory

(2013) K.B. Gordon et al.   BRITISH JOURNAL OF DERMATOLOGY

Energy-restricted, n-3 polyunsaturated fatty acids-rich diet improves the clinical response to immuno-modulating drugs in obese patients with plaque-type psoriasis: a randomized control clinical trial

(2013) Bruna Guida et al.   CLINICAL NUTRITION

Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study

(2013) Vibeke Strand et al.   Health and Quality of Life Outcomes

9-cis–Rich β-Carotene Powder of the AlgaDunaliellaReduces the Severity of Chronic Plaque Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

(2013) Shoshana Greenberger et al.   JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION

Betamethasone valerate dressing is non-inferior to calcipotriol-betamethasone dipropionate ointment in the treatment of patients with mild-to-moderate chronic plaque psoriasis: results of a randomized assessor-blinded multicentre trial

(2013) J.-P. Ortonne et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate-to-severe psoriasis: results from the PRISTINE trial

(2013) D. Thaçi et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study

(2013) K.A. Papp et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies

(2013) P.L. Mattei et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis

(2013) C. Mamolo et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

(2013) Iain B McInnes et al.   LANCET

Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24-Week Patient-Reported Outcome Results of a Phase III, Multicenter Study

(2013) D. Gladman et al.   ARTHRITIS CARE & RESEARCH

Effect of Weight Loss on the Severity of Psoriasis

(2013) Peter Jensen et al.   JAMA Dermatology

An educational programme for patients with psoriasis and atopic dermatitis: a prospective randomized controlled trial

(2012) J. Bostoen et al.   BRITISH JOURNAL OF DERMATOLOGY

Evaluation of the impact of writing exercises interventions on quality of life in patients with psoriasis undergoing systemic treatments

(2012) S. Tabolli et al.   BRITISH JOURNAL OF DERMATOLOGY

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years

(2012) A.B. Kimball et al.   BRITISH JOURNAL OF DERMATOLOGY

Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension

(2012) K. Reich et al.   BRITISH JOURNAL OF DERMATOLOGY

A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis

(2012) J.P. Ortonne et al.   BRITISH JOURNAL OF DERMATOLOGY

A randomized controlled single-blind clinical trial on 84 outpatients with psoriasis vulgaris by auricular therapy combined with optimized Yinxieling Formula (银屑灵优化方)

(2012) Chuan-jian Lu et al.   Chinese Journal of Integrative Medicine

S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update

(2012) Alexander Nast et al.   JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial)

(2012) Robert Strohal et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: Results from a randomized, double-blind, placebo-controlled phase 2 / 3 trial

(2012) Hidemi NAKAGAWA et al.   JOURNAL OF DERMATOLOGY

Dermatology Life Quality Index (DLQI): A Paradigm Shift to Patient-Centered Outcomes

(2012) Andrew Y. Finlay et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study

(2012) A.B. Kimball et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial

(2012) Kim Papp et al.   LANCET

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

(2012) Kim A. Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

(2012) Craig Leonardi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Quality of life and assessment after local application of sulphurous water in the home environment in patients with psoriasis vulgaris: A randomised placebo-controlled pilot study

(2012) Juan José Gálvez Galve et al.   European Journal of Integrative Medicine

Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)

(2011) J. Barker et al.   BRITISH JOURNAL OF DERMATOLOGY

Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study

(2011) J.-H. Saurat et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)

(2011) Tsen-Fang Tsai et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept

(2011) Charles W. Lynde et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Qualitative assessment of the content validity of the Dermatology Life Quality Index in patients with moderate to severe psoriasis

(2011) Shima Safikhani et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial

(2011) Atsuyuki IGARASHI et al.   JOURNAL OF DERMATOLOGY

A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis

(2011) Kenneth B. Gordon et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Patient-centered online management of psoriasis: A randomized controlled equivalency trial

(2011) Cindy J. Chambers et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens

(2011) R. Gniadecki et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

A pilot randomized controlled trial to examine the feasibility and efficacy of an educational nursing intervention to improve self-management practices in patients with mild-moderate psoriasis

(2011) S.J. Ersser et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study

(2011) R. Bissonnette et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Efficacy and Safety of Adalimumab among Patients with Moderate to Severe Psoriasis with Co-Morbidities

(2010) Alexa B. Kimball et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study

(2010) D. Thaçi et al.   BRITISH JOURNAL OF DERMATOLOGY

Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial

(2010) Arthur Kavanaugh et al.   CURRENT MEDICAL RESEARCH AND OPINION

Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial

(2010) Hideshi Torii et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study

(2010) Akihiko ASAHINA et al.   JOURNAL OF DERMATOLOGY

Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial

(2010) Richard G. Langley et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: A randomized clinical trial

(2010) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

A randomized clinical trial in psoriasis: synchronous balneophototherapy with bathing in Dead Sea salt solution plus narrowband UVB vs. narrowband UVB alone (TOMESA-study group)

(2010) A Klein et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double-blind, placebo-controlled study

(2010) I. Möller et al.   OSTEOARTHRITIS AND CARTILAGE

Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial

(2009) K. Kragballe et al.   BRITISH JOURNAL OF DERMATOLOGY

British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009

(2009) C.H. Smith et al.   BRITISH JOURNAL OF DERMATOLOGY

Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial

(2009) M. Lebwohl et al.   BRITISH JOURNAL OF DERMATOLOGY

Methotrexate versus traditional Chinese medicine in psoriasis: a randomized, placebo-controlled trial to determine efficacy, safety and quality of life

(2009) S. G. Y. Ho et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

A Comparison of Mycophenolate Mofetil with Ciclosporine for the Treatment of Chronic Plaque-Type Psoriasis

(2009) Stefan Beissert et al.   DERMATOLOGY

Once-Weekly Administration of Etanercept 50 mg Improves Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis

(2009) Kristian Reich et al.   DERMATOLOGY

Mind the MIC: large variation among populations and methods

(2009) Caroline B. Terwee et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Mometasone furoate 0.1% and salicylic acid 5% vs. mometasone furoate 0.1% as sequential local therapy in psoriasis vulgaris

(2009) G-S Tiplica et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study

(2009) E Daudén et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis

(2009) TA Luger et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial

(2009) JP Ortonne et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

A prospective, randomized clinical trial comparing topical aloe vera with 0.1% triamcinolone acetonide in mild to moderate plaque psoriasis

(2009) C Choonhakarn et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

(2009) Alice Gottlieb et al.   LANCET

Burden of skin diseases

(2009) Mohammad KA Basra et al.   Expert Review of Pharmacoeconomics & Outcomes Research

The Combination of Etanercept and Methotrexate Increases the Effectiveness of Treatment in Active Psoriasis Despite Inadequate Effect of Methotrexate Therapy

(2008) C Zachariae et al.   ACTA DERMATO-VENEREOLOGICA

Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis

(2008) S.R. Feldman et al.   BRITISH JOURNAL OF DERMATOLOGY

Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis

(2008) Kristian Reich et al.   CURRENT MEDICAL RESEARCH AND OPINION

Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: Results from a randomized, controlled Phase III study

(2008) Dennis A Revicki et al.   Health and Quality of Life Outcomes

Different treatment outcomes with different formulations of clobetasol propionate 0.05% for the treatment of plaque psoriasis

(2008) Serena Mraz et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study

(2008) K Papp et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

(2007) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Patient-Reported Outcomes and Health-Care Resource Utilization in Patients with Psoriasis Treated with Etanercept: Continuous versus Interrupted Treatment

(2007) Joel M. Gelfand et al.   VALUE IN HEALTH